Hakozaki Y, et al. - A comparative evaluation was pursued of the detection rates for clinically significant prostate cancer (CSPC) between magnetic resonance imaging and ultrasonography (MRI/US)-fusion-targeted biopsy (TB), systematic biopsy (SB) and combination of TB and SB. Researchers demonstrated that prostate imaging reporting and data system version 2 (PI-RADS v2) category 4 and an age of <65 years served as the predictive factors of upgrading the Gleason score by MRI/US-fusion TB. Hence, MRI/US-fusion TB could be suitable for patients with those characteristics.